Success Metrics

Clinical Success Rate
93.1%

Based on 27 completed trials

Completion Rate
93%(27/29)
Active Trials
1(3%)
Results Posted
56%(15 trials)
Terminated
2(6%)

Phase Distribution

Ph not_applicable
2
6%
Ph phase_2
3
9%
Ph phase_4
7
21%
Ph phase_3
11
33%

Phase Distribution

0

Early Stage

3

Mid Stage

18

Late Stage

Phase Distribution23 total trials
Phase 2Efficacy & side effects
3(13.0%)
Phase 3Large-scale testing
11(47.8%)
Phase 4Post-market surveillance
7(30.4%)
N/ANon-phased studies
2(8.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

27 of 30 finished

Non-Completion Rate

10.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

33

all time

Status Distribution
Active(1)
Completed(27)
Terminated(3)
Other(2)

Detailed Status

Completed27
unknown2
Terminated2
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
33
Active
1
Success Rate
93.1%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (13.0%)
Phase 311 (47.8%)
Phase 47 (30.4%)
N/A2 (8.7%)

Trials by Status

completed2782%
unknown26%
withdrawn13%
recruiting13%
terminated26%

Recent Activity

Clinical Trials (33)

Showing 20 of 33 trialsScroll for more
NCT05214573

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Completed
NCT01242215Phase 3

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients

Completed
NCT05751525

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

Recruiting
NCT03921242

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

Completed
NCT03936023

Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims

Completed
NCT03936036

Replication of the CARMELINA Diabetes Trial in Healthcare Claims

Completed
NCT03936062

Replication of the TECOS Diabetes Trial in Healthcare Claims

Completed
NCT05102071

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Withdrawn
NCT03761134Phase 3

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

Terminated
NCT02941367Phase 4

Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

Completed
NCT03066830Phase 3

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

Completed
NCT04192292Not Applicable

Study of Sulphonylurea Synergy With DPP4 Inhibitors

Completed
NCT02624830Phase 4

Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)

Unknown
NCT04239586Phase 4

Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes

Unknown
NCT02111096Phase 2

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Terminated
NCT03983551Phase 4

Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

Completed
NCT02954692Phase 4

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Completed
NCT02532855Phase 3

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Completed
NCT01972724Phase 4

Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy

Completed
NCT02624817Phase 4

Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes

Completed

Drug Details

Intervention Type
DRUG
Total Trials
33